In their Comment,1 James T Topham and colleagues emphasise the vital role that data sharing has in studying rare diseases. They cite reluctance to share as a key factor constraining progress in cancer research, with a main frustration being the restrictive policies of the General Data Protection Regulation (GDPR). They highlight the work of the International Cancer Genome Consortium as a case study of how sharing genomic data poses challenges.